Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAmortization of GoodwillAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Avanos Medical (AVNS) Long-Term Debt Issuances (2013 - 2022)

Avanos Medical recorded quarterly Long-Term Debt Issuances of $125.0 million in Q2 2022, little changed quarter-over-quarter from $125.0 million in Q1 2022.

Avanos Medical's Long-Term Debt Issuances history runs 3 years deep, the most recent figure standing at $125.0 million for Q2 2022.

  • In Q2 2022, Long-Term Debt Issuances changed N/A year-over-year to $125.0 million; the TTM figure through Mar 2023 stood at $125.0 million (changed 0.0% YoY), while the FY2022 annual figure was $250.0 million, changed N/A from the prior year.
  • Long-Term Debt Issuances came in at $125.0 million for Q2 2022 at Avanos Medical, roughly flat from $125.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $125.0 million in Q1 2022 to a low of $125.0 million in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 19.86 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 11.71 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 1.15 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Avanos Medical 1.17 Bn 1.10 Bn 94.20 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2022 125.00 Mn
Jun 30, 2022 125.00 Mn
Mar 31, 2022 125.00 Mn
Mar 31, 2022 125.00 Mn
Dec 31, 2014 636.10 Mn
Dec 31, 2014 636.10 Mn
Sep 30, 2014 600,000.00
Sep 30, 2014 600,000.00
Jun 30, 2014 1.00 Mn
Jun 30, 2014 1.00 Mn
Mar 31, 2014 300,000.00
Mar 31, 2014 300,000.00
Dec 31, 2013 4.00 Mn
Dec 31, 2013 4.00 Mn